clinical trial · NCT02964936
A Study of Intermittent Oral Dosing of ASP1517 in ESA-untreated Chronic Kidney Disease Patients With Anemia
Chronic Kidney Diseaseroxadustat
brief summary
The objective of this study is to evaluate the efficacy and the safety when ASP1517 is intermittently administered in Erythropoiesis Stimulating Agent (ESA)-untreated non-dialysis chronic kidney disease patients with anemia.
started
Jan 11, 2017
primary completion
Aug 15, 2018
completion
Aug 15, 2018
last updated
Oct 31, 2024
official title
A Phase 3, Multicenter, Randomized, 2-Arm, Open-label Study of Intermittent Oral Dosing of ASP1517 for the Treatment of Anemia in Erythropoiesis Stimulating Agent-untreated Chronic Kidney Disease Patients Not on Dialysis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol